Sustained first remission in an adolescent with hepatosplenic T-cell lymphoma treated with T-cell leukemia induction, nucleoside analog-based consolidation, and early hematopoietic stem cell transplant.

Abstract

Hepatosplenic T-cell lymphoma (HTCL) is a rare malignancy. Prognosis is poor with only a few case reports of long-term survivors. While HTCL universally involves the bone marrow, the condition has been most often treated with multimodal lymphoma specific chemotherapy. We report a durable, sustained first remission in an adolescent treated for HTCL who received induction therapy according to a high risk T-cell leukemia regimen, a nucleoside analog-based consolidation, and allogeneic transplantation associated with GVHD.

• Authors: Eric Schafer, Allen Chen, Robert J Arceci
• Journal: Pediatric blood & cancer (Pediatr Blood Cancer) Vol. 53 Issue 6 Pg. 1127-9 (Dec 2009) ISSN: 1545-5017 [Electronic] United States
• PMID: 19479793 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Nucleosides

Topics

• Adolescent
• Antineoplastic Agents (therapeutic use)
• Female
• Hematopoietic Stem Cell Transplantation (methods)
• Humans
• Leukemia, T-Cell (drug therapy)
• Liver Neoplasms (therapy)
• Lymphoma, T-Cell (pathology, therapy)
• Nucleosides (therapeutic use)
• Remission Induction (methods)
• Splenic Neoplasms (therapy)
• Treatment Outcome